Brofaromine

Brofaromine

Systematic (IUPAC) name
4-(7-bromo-5-methoxybenzofuran-2-yl)piperidine
Clinical data
Routes of administration	Oral
Legal status
Legal status	℞ (Prescription only)
Pharmacokinetic data
Protein binding	98%
Biological half-life	9-14 hours
Identifiers
CAS Number	63638-91-5 Y
ATC code	none
PubChem	CID 44571
ChemSpider	40549 Y
UNII	6WV4B8Q07H Y
KEGG	D02560 Y
ChEMBL	CHEMBL160347 Y
Chemical data
Formula	C14H16BrNO2
Molar mass	310.186 g/mol
SMILES Brc3cc(OC)cc1c3oc(c1)C2CCNCC2
InChI InChI=1S/C14H16BrNO2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16H,2-5H2,1H3 Y Key:WZXHSWVDAYOFPE-UHFFFAOYSA-N Y
(verify)

Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.

Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants.

Pharmacology

Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.